Increasing Omega-3 Intake May Boost Cognitive Flexibility

This article originally appeared here.
Share this content:
Increasing Omega-3 Intake May Boost Cognitive Flexibility
Increasing Omega-3 Intake May Boost Cognitive Flexibility

(HealthDay News) -- Consuming more omega-3 fatty acids may benefit patients at risk for Alzheimer's disease, according to a new study published online May 21 in Frontiers in Aging Neuroscience.

Researchers looked at 40 cognitively healthy adults, aged 65 to 75, who had the gene variant APOE ε4.

Those who consumed higher amounts of two omega-3 fatty acids found in fish -- docosahexaeonic acid (DHA) and eicosapentaenoic acid (EPA) -- did better on tests that assessed their cognitive flexibility. They also had a larger anterior cingulate cortex, the researchers said. The findings suggest that consuming DHA and EPA omega-3 fatty acids might improve mental flexibility by boosting the size of the anterior cingulate cortex, according to the authors of the study.

"Recent research suggests that there is a critical link between nutritional deficiencies and the incidence of both cognitive impairment and degenerative neurological disorders, such as Alzheimer's disease," study co-leader Aron Barbey, Ph.D., a professor of neuroscience, psychology, and speech and hearing science at the University of Illinois in Urbana, said in a university news release. "Our findings add to the evidence that optimal nutrition helps preserve cognitive function, slow the progression of aging, and reduce the incidence of debilitating diseases in healthy aging populations."

Funding for the study was provided by Abbott Nutrition, a division of Abbott, a maker of health care products.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »